Athersys, Inc. (ATHX)
After hours:
- Business Wire
Athersys Announces Successful Type B Meeting with the FDA
CLEVELAND, March 22, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the U.S. Food & Drug Administration (FDA). Held on March 21, 2023, the meeting addressed Athersys’ proposed modifications that seek to establish primary and secondary endpoints that it believes best reflect the full potent
- Business Wire
Athersys Expands IP Protection with First New Patent for SIFU® Technology
CLEVELAND, February 28, 2023--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that the United States Patent and Trademark Office has granted the Company a new patent for its novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU®). This U.S. Patent No. 11,566,834, titled "Apparatus and Method for Cryostorage and Manipulation of a Plurality of Container Units," ad
- American City Business Journals
Athersys is a 'very different company' from a year ago, CEO says
In June 2022, Athersys embarked on a financial and operational restructuring to lower its cost and conserve cash while completing the testing and commercialization of its adult stem-cell therapy.
